Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue
Boosting serotonin in the brain: is it time to revamp the treatment of depression?
Reconsidering GHB: orphan drug or new model antidepressant?
The hidden third: improving outcome in treatment-resistant depression